PPD04.01 Survival Associations of T cell Clusters with Immunotherapy in Mesothelioma

Immune checkpoint blockade therapy (ICBT) is a first-line treatment option for patients with pleural mesothelioma with the approval of ipilimumab and nivolumab. It has been challenging to identify predictive biomarkers of benefit with ICBT in mesothelioma given its low tumor mutation burden. Since ICBTs enable adaptive anti-tumor immune responses, we investigated T-cell receptor (TCR) associations with survival outcomes from participants of two ICBT clinical trials.